

Investor Newsletter

Issue **04** 2016



First-in-Man Clinical Trials of Firesorb™ Completes Patient Enrollment

Shanghai MicroPort Medical (Group) Co ("MicroPort®") has completed the patient enrollment for the perspective, single group observation, First-in-Man ("FIM") clinical trial of evaluating the safety and efficacy of Firesorb™ Bioresorbable Rapamycin Target Eluting Coronary Scaffold System ("Firesorb™") in the treatment of coronary heart diseases. A total of 45 patients are enrolled in the trial after it was launched on January 18.

The preliminary result of the clinical trial shows that the enrolled patients are suitable for the operation, and the implantation technique conforms to the standard with proper scaffold size selection, full pre-dilation that makes the scaffold easily reach the lesion, high percentage post-dilation, and proper endovascular imaging guidance.

Professor Bo Xu of the Fuwai Hospital said, as the first second-generation bioresorbable scaffold that has completed patient enrollment for FIM clinical trial in the world, Firesorb™'s primary advantages lie in its ultra-thin wall and target eluting design. The completion of patient enrollment has provided the first evidence of Firesorb™'s safety and efficacy.

Once the enrollment is completed, clinical follow-up will be performed in the 45 patients in one month, six months, one year, two years, three years, four years and five years after scaffold implantation. Currently, MicroPort® is preparing to carry out a large scale, multi-center clinical trial of Firesorb™.

"The completion of the patient enrollment of the FIM clinical trial lays a great foundation for the following clinical studies of this cardiovascular device," said Dr. Qiyi Luo, Chief Technology Officer of MicroPort®. "We hope the results of these clinical studies would pave the way for Firesorb™'s market launch in China, so as to offer more solutions to patients with coronary artery diseases."



MicroPort® Introduces its Transcatheter Aortic Valve in China Valve

MicroPort® recently attended the Second China Valve (Hangzhou) to promote its in-house developed Self-expanding Transcatheter Aortic Valve.

The conference, hosted by the Second Affiliated Hospital of Zhejiang University School of Medicine, provides up-to-date information of the development of Transcatheter Aortic Valve Replacement ("TAVR") through academic lectures, case studies, panel discussions and simulating operations. Its Bureau was composed of more than 10 renowned experts from Germany, France, Canada, the US and the UK. Professor Runlin Gao of Fuwai Hospital of Chinese Academy of Medical Sciences, Professor Junbo Ge of Zhongshan Hospital, and Professor Yaling Han of the General Hospital of Shenyang Military, attended the conference.

The conference made a live broadcasting of TAVR therapy using MicroPort® Self-expanding Transcatheter Aortic Valve, Transcatheter Aortic Valve Delivery System and Valve Balloon Dilatation Catheter. Performed by Professor Jian'an Wang of the Second Affiliated Hospital of Zhejiang University School of Medicine and his team, the surgery achieved successful outcome and attracted wide attention from the audience.

Meanwhile, Professor Daxin Zhou of Zhongshan Hospital introduced the clinical advances of the Self-expanding Transcatheter Aortic Valve and Delivery System in detail. He pointed out: "MicroPort® products are proved effective as they significantly reduce aortic valve gradient. They are also safe and easy to operate."

TAVR is a revolutionary procedure to treat patients with aortic valve disease. With less pain and faster recovery, TAVR could bring better experience for patients in most cases. For patients who are too sick or too old for conventional operations, it could mean a life-saving opportunity. It is expected that MicroPort's domestically made valve will promote the use of TAVR so as to benefit more patients in China.

MicroPort®'s Self-expanding Transcatheter Aortic Valve is designed to have better coaxiality, anchoring and crossing ability, and most importantly it can reduce perivalvular leak. It is also easier to use with motorized handle.

MicroPort® Attends the 18th SCC 2016

MicroPort® recently attended the 18th South China International Congress of Cardiology ("SCC 2016") held in Guangzhou, to promote our in-house developed Firehawk® Rapamycin Target Eluting Coronary Stent ("Firehawk®").

The SCC 2016 values Science, Creation and Concord. It provides a platform for domestic and international cardiovascular specialists to exchange ideas on new thoughts and breakthroughs in the prevention and treatment of cardiovascular diseases.

During the conference, Professor Bo Xu of Fuwai Hospital delivered a speech on the innovations of cardiovascular devices, in which he released the four-year research results of Firehawk® while announcing that its five-year follow-up studies will be completed this year. He also introduced in particular the TARGET All Comer clinical trial, a prospective, multi-center, randomized clinical trial to evaluate Firehawk®'s safety and efficacy.

Meanwhile, Professor Bo Xu shared the updates of the First-in-Man ("FIM") Clinical Trials of Firesorb™. He presented three successful cases in the FIM clinical trials, one of which showed the implanted scaffold has started resorbing. In addition, Professor Xu gave a brief introduction to Firesorb™ FUTURE II Clinical Trial that is about to launch.

Firehawk®
Rapamycin
Target Eluting
Coronary Stent
System

MicroPort® and Yizheng Municipal Government Establishes "Shanghai-Yizheng Healthcare Cooperation Project"

MicroPort® and Yizheng Municipal Government recently held the signing and opening ceremony of "Shanghai-Yizheng Healthcare Cooperation Project" in Yizheng of Jiangsu Province. Zhenyu Zhang, the Secretary of Yizheng Municipal Committee, and Dr. Zhaohua Chang, Chairman and Chief Executive Officer of MicroPort®, attended and addressed the ceremony.

In partnership with Yizheng People's Hospital and University of Shanghai for Science and Technology, MicroPort® established Engineering Research Center of Modern Micro-invasive Medical Device and Technology of Ministry of Education & Yizheng Collaborative Innovation Center. Meanwhile, MicroPort® launched MicroPort® Telemedicine Yizheng Demonstration Center with Yizheng People's Hospital. Telemedicine service of the network service platform "Life Line Live" (www.1o2o.com), supported by MicroPort®'s subsidiary MicroPort Online Medical Technology (Shanghai) Co ("MicroPort® Online"), is applied to these two centers to offer doctors with tele-consultation, real-time intraoperative guidance and online training service, allowing doctors and patients in less-developed areas to enjoy high-quality medical resources.

Three consultations were convened in the Telemedicine Center of Yizheng Hospital on the day of the opening ceremony, including tele-consultation by Professor Changlin Mei of Shanghai Changzheng Hospital for a patient with kidney disease, tele-consultation by surgeons of Xuanwu Hospital Capital Medical University for a neurological patient, and tele-consultation by surgeons of Beijing Youan Hospital for a patient with infectious disease. Meanwhile, Professor Dadong Zhang of Shanghai Yodak Cardiothoracic Hospital provided remote guidance in a coronary surgery through the platform.

The Shanghai-Yizheng Healthcare Cooperation Project enables patients to obtain professional treatment and diagnosis from a remote expert, avoiding wasting the time and money to physically travel to see the doctor in person. In addition, the project facilitates experienced surgeons to give lectures on special topics and complex cases, which helps to improve the theoretical knowledge level and clinical skills of local medical staff in Yizheng. MicroPort® will continue to promote the "Life Line Live" platform and offer telemedical service to a larger number of patients and surgeons in second- and third-tier cities in China.



MicroPort® OrthoRecon Launches "Fast Recovery" Training Course and MicroPort® Arthroplasty Training Center

In partnership with Shanghai Sixth People's Hospital, Suzhou MicroPort OrthoRecon Co ("MicroPort® OrthoRecon") recently launched MicroPort® OrthoRecon "Fast Recovery" training course in Shanghai, which attracted over 80 orthopedic professionals from all over the country.

The course was chaired by Professor Xianlong Zhang, Director of Joint Surgical Department of Shanghai Sixth People's Hospital. Professor Yunsu Chen, Professor Qi Wang and Professor Hao Shen served as lecturers. Professor Yan Wang, Head of Chinese Association of Orthopaedic Surgeons, Professor Xisheng Weng, Vice Chairman of Chinese Orthopaedic Association, Professor Kunzheng Wang, Vice Chairman of Chinese Orthopaedic Association, Professor Tiebing Qu, President of Chinese Knee Society, and Professor Bing Xia, Head of Arthroscopy Branch of Zhejiang Orthopedic Association, were invited as guest speakers.

Prior to the commencement of the course, MicroPort® hosted the opening ceremony of MicroPort® Arthroplasty "Fast Recovery" Training Center and issued the letter of appointment for Director of the training center to Professor Xianlong Zhang. Established by MicroPort® OrthoRecon and Shanghai Sixth People's Hospital, the training center aims to promote the "Fast Recovery" Concept through providing surgeons with various training of arthroplasty surgery techniques, such as the newly launched MicroPort® OrthoRecon "Fast Recovery" training course.

The MicroPort® OrthoRecon "Fast Recovery" training course covered a wide range of topics including Approach for Minimally Invasive ("MIS") Total Hip Arthroplasty ("THA"), Anatomy and Clinical Significance of MIS THA, Indications and Pre-operative Preparation of SuperPath™ Micro-posterior THA Surgical Technique ("SuperPath™"), Surgical Technique of SuperPath™, Analysis of Difficulties in using SuperPath™, Clinical Result of SuperPath™, Measures and Technique to Reduce Blood Loss in Arthroplasty, VTE Prevention in "Fast Recovery" Approach, Infection Prevention in "Fast Recovery" Approach, Post-operative Rehabilitation of MIS, Live Operation Demonstrations of MicroPort® Orthopedics Medial-Pivot Knee and SuperPath™ surgeries.

Professor Xianlong Zhang said, MicroPort® OrthoRecon "Fast Recovery" training course not just provided theoretical knowledge but enabled the trainees to get in-depth discussions, direct guidance and other interactive opportunities with the lecturers. He suggested organizing more small-scaled courses with focused topics in the future, to facilitate trainees to apply what they learnt to clinical practice.



MicroPort® Arthroplasty Technique Training Center Launched in the Second Affiliated Hospital of Xi'an Jiaotong University

MicroPort® OrthoRecon and the Second Affiliated Hospital of Xi'an Jiaotong University recently hosted the opening ceremony of MicroPort® Arthroplasty Technique Training Center in Xi'an.

Professor Yisheng Wang, Deputy Chief of Joint Surgery Branch of Chinese Orthopaedic Association, Professor Kunzheng Wang, Vice Chairman of Chinese Orthopaedic Association, Professor Tiebing Qu, President of Chinese Knee Society, Professor Bing Xia, Head of Arthroscopy Branch of Zhejiang Orthopedic Association, Simon Chen, General Manager of MicroPort® OrthoRecon, and over 80 orthopedic specialists from all over the country, attended the ceremony.

The training center aims to promote the "Fast Recovery" Concept through providing surgeons with various training of arthroplasty surgery technique. On the launch day, the center started up a training course on "Fast Recovery"& MIS Technique and Concept, and Professor Kunzheng Wang and Professor Bing Xia were invited as the lecturers.

The course covered a wide range of topics including the Development History and Clinical Significance of MIS Arthroplasty, the Anatomy and Approach of SuperPath™, Analysis of Difficulties in using SuperPath™, Medial-Pivot Knee System, Post-operative Rehabilitation of MIS Arthroplasty, and Live Operation Demonstrations of SuperPath™ surgeries.



MicroPort® Asia-Pacific Knee Arthroplasty Training Center Established in Shanghai

On April 25, in partnership with Shanghai Ninth People's Hospital, Shanghai MicroPort Orthopedics Co established MicroPort® Asia-Pacific Knee Arthroplasty Training Center in Shanghai Ninth People's Hospital. Dr. You Wang of Shanghai Ninth People's Hospital, served as the Director of the training center, and Dr. Tiebing Qu as the Honorary Director.

The opening ceremony was hosted by Dr. You Wang. Several professionals including Dr. Tiebing Qu, Dr. Kerong Dai and Dr. Changqian Wang of Shanghai Ninth People's Hospital, Dr. Liu Yang of Southwest Hospital, Yihe Hu of Xiangya Hospital Central South University, Dr. Yingzhen Wang of the Affiliated Hospital of Qingdao University, Dr. Yuhua Jia of Qilu Hospital of Shandong University, and MicroPort senior management including Martin Sun and Simon Chen came to attend and address the ceremony.



First Medial Pivot Total Knee Arthroplasty Training Course in Shanghai

On April 24, MicroPort® hosted the First Medial Pivot Total Knee Arthroplasty (“TKA”) Training Program in Shanghai Ninth People’s Hospital, which attracted over 50 doctors and experts. The faculties shared with the attendees the development trend of TKA in China, knee kinematics, the principles of TKA, correct alignment, soft tissue balance skills, bone resection skills, post-operative flexion and function. Trainees also learnt knowledge about per-operative plan, how to correct mechanical axis, bone resection and perioperative management through three surgery demonstrations.



Fast Recovery and MIS Course and Surgery Demonstration in Zhejiang

From April 21 to April 22, MicroPort® held the Third 2016 Fast Recovery and MIS Course and Surgery Demonstration in Zhejiang People's Hospital, and a total of 16 people attended the training. The course covered six major topics including Anatomy Main Point and Surgical Approach for SuperPath™, Indication and Pre-Operative Preparation of SuperPath™, Post-operative Rehabilitation of SuperPath™ Approach, Surgical Technique of SuperPath™, Analysis of Difficulties in using SuperPath™, and Clinical Outcome of SuperPath™.





MicroPort® EP Makes the First Live Broadcasting of Columbus® Surgery

Shanghai MicroPort EP MedTech Co ("MicroPort® EP") recently attended the 18th South China International Congress of Cardiology in Guangzhou, and for the first time live broadcasted a surgery using Columbus® 3D EP Navigation System ("Columbus®") in China.

The operation was conducted by Professor Xianhong Fang of Guangdong General Hospital to treat a patient suffered from frequent ventricular premature beats with radio-frequency ablation. Columbus®'s RTM (Real time mapping), which provides accurate geometric reconstruction of intra cardiac chambers, was used to map the earliest activation site for the ablation. Professor Pihua Fang with Fuwai Hospital of Chinese Academy of Medical Sciences made a clear narration of the operation. The excellent performance of Columbus® attracted wide attention from the audience and was highly recognized by experts in attendance.

Columbus®, designed for the diagnosis of complex arrhythmias, is the first domestically developed 3D EP navigation system that features real time electromagnetic device tracking with cardiac motion compensation. It offers vivid 3D simulation of the catheter deflectable segment and accurate geometric reconstruction of intra cardiac chambers to facilitate physicians in the treatment of complex arrhythmias.


Columbus® gains the registration certificate of China Food and Drug Administration in 2016. Its first surgery live broadcasting will help to open up the China market and benefit more patients with cardiac arrhythmias in the country.

First Use of Evermend™ Occluder in Shymkent of Kazakhstan

A batch of Evermend™ Occluder, in-house developed by Dongguan Kewei Medical Instrument Co ("Dongguan Kewei"), were successfully implanted in Shymkent Children's Hospital, marking the first use of Evermend™ Occluder in the southern part of Kazakhstan.

In Shymkent Children's Hospital, a total of 17 operations were conducted, using Evermend™ PDA Occluder and Delivery System or Evermend™ ASD Occluder and Delivery System. The patients, aged from 4 to 9 years old, all responded well to the treatment, and no adverse reaction occurred after operations. Evermend™ Occluders were spoke highly by doctors performed the operations for their high quality and affordable price.

Evermend™ PDA Occluder and Delivery System, and Evermend™ ASD Occluder and Delivery System are designed respectively for the interventional treatment of patent ductus arteriosus and congenital atrial septal defect. Once placed in the lesion, the occluder effectively blocks abnormal blood flow so as to repair or rebuild the defect. These products enable surgeons to provide their patients with minimally invasive surgical procedures that result in less pain, shorter hospital stay and quicker recovery compared to traditional surgeries.



Evermend™ Occluders gained market approval in Kazakhstan in December, 2015, and are expected to benefit more patients with congenital heart disease in the country.



MicroPort® Online "Life Line Live" Officially Launched

The network service platform "Life Line Live" (www.1o2o.com) of MicroPort® Online, a subsidiary of MicroPort®, was officially launched during the Third International Conference on Health and Internet of Things & the Inaugural Meeting of the Shanghai Health Alliance Networking, hosted by MicroPort® and Shanghai Internet of Things Industry Association in Shanghai on March 30.

Utilizing the latest concepts and technologies of the Connected Health, the platform "Life Line Live" aims to provide medical service tailored to the individual patient and deliver patient care outside of the hospital or doctor's office. The platform fully leverages MicroPort®'s strength by combining its professional medical service with advanced IT technologies related to the Internet, the Internet of Things, and Big Data Processing Analytics.

The service of the "Life Line Live" covers five areas including Personalized Medicine, Tele-medicine, Medical Education, Rehabilitation Management and Medical Big Data, and the first three of them are already online. Its Personalized Medicine service will offer surgical plans tailored to the individual patient based on the Patient Case Management System ("PCMS"). The Tele-medicine service will enable doctors or patients to obtain remote clinical healthcare, tele-consultation and real-time intraoperative guidance, so as to allow those in less-developed areas to enjoy high-quality medical resources. The service of Medical Education will provide users with operation live broadcasting or recorded broadcasting, and online training video/audio documents. ▶

Meanwhile, MicroPort® initiated the launch of the Committee of Precise Intervention & Implantation Medicine during the conference. The committee is consisted of intervention and implantation medical device manufacturers, professional providers of 3D reconstruction of medical images, and Internet medicine related companies. Currently its members include MicroPort® and several of its subsidiaries, China Mobile, Nanjing Fujitsu, and University of Shanghai for Science and Technology.

The committee focuses on providing high-end personalized medical service to patients, based on the "Life Line Live" platform of MicroPort® Online. Listed as one of the three professional committees of Shanghai Health Alliance Networking, the Committee of Precise Intervention & Implantation Medicine will work closely with the other two committees to provide precise, convenient and safe medical service to patients and doctors.

During the forum on Precise Intervention & Implantation Medicine, Dr. Yiyong Sun, President of MicroPort® EP, delivered a speech on mobile ECG monitoring, introducing the EP ECG patch to the audience and analyzing the development trend of ECG monitoring in the Internet era. Other representatives from the committee members also shared cutting-edge technologies in the field of the Healthcare Internet of Things, such as techniques and material of 3D Printing and Cardiac Intelligent Simulation technologies.



Investor Newsletter

Issue **04** 2016



For more information, please contact:

Hongbin Sun

Chief Financial Officer

Shanghai MicroPort Medical (Group) Co., Ltd. (HQ)

Tel: (86)(21) 38954600

Email: ir@microport.com